Ascendis Pharma Receives MHRA Approval for YORVIPATH (Palopegteriparatide) Against Chronic Hypoparathyroidism in Great Britain
Shots:
- The MHRA has granted marketing authorization to Ascendis’ Yorvipath (Palopegteriparatide) for the treatment of adults with chronic hypoparathyroidism, along with ODD (10 yrs. market exclusivity in Great Britain)
- MHRA approval is based on same dossier submitted for Yorvipath’s EU approval in Nov’23
- Yorvipath (developed as TransCon PTH), a prodrug of parathyroid hormone (PTH 1-34) administered QD; also being developed in US, Japan and other countries for chronic hypoparathyroidism
Ref: Ascendis Pharma | Image: Ascendis Pharma
Related News:- Ascendis Enters into Collaboration with Teijin Limited to Develop & Commercialize TransCon hGH, TransCon PTH, & TransCon CNP in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
